Viatris Inc. reported its financial results for the second quarter of 2025, surpassing Wall Street estimates for both profit and revenue. The company announced total revenue of $3.58 billion, which, despite being a 5.6% decrease year-over-year, exceeded analysts' expectations.
The company reported a U.S. GAAP net loss of $4.6 million, translating to a loss of less than 1 cent per share. However, Viatris's adjusted non-GAAP profit was $0.62 per share, which was 11.6% above analysts' consensus estimates, indicating strong operational performance.
Viatris reaffirmed its full-year revenue guidance of $13.75 billion, providing stability and confidence in its outlook for the remainder of 2025. The demand for its branded drugs in China was a key factor contributing to the positive performance during the quarter.
Management highlighted significant progress in its pipeline, noting that five of its six anticipated Phase 3 readouts have shown positive results. These advancements in the late-stage development pipeline are crucial for Viatris's long-term growth strategy and its pivot towards a more innovative portfolio.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.